Related Experiment Video
Updated: Feb 17, 2026
Using Optogenetics to Reverse Neuroplasticity and Inhibit Cocaine Seeking in Rats
Published on: October 5, 2021
Minocycline plus N-Acetylcysteine Reduce Behavioral Deficits and Improve Histology with a Clinically Useful Time
Michael A Sangobowale1, Natalia M Grin'kina2, Kristen Whitney1
1School of Graduate Studies, SUNY-Downstate Medical Center, Brooklyn, New York.
Abstract:
There are no drugs to manage traumatic brain injury (TBI) presently. A major problem in developing therapeutics is that drugs to manage TBI lack sufficient potency when dosed within a clinically relevant time window. Previous studies have shown that minocycline (MINO, 45 mg/kg) plus N-acetylcysteine (NAC, 150 mg/kg) synergistically improved cognition and memory, modulated inflammation, and prevented loss of oligodendrocytes that remyelinated damaged white matter when first dosed 1 h after controlled cortical impact (CCI) in rats. We show that MINO (45 mg/kg) plus NAC (150 mg/kg) also prevent brain injury in a mouse closed head injury (CHI) TBI model. Using the CHI model, the concentrations of MINO and NAC were titrated to determine that MINO (22.5 mg/kg) plus NAC (75 mg/kg) was more potent than the original formulation. MINO (22.5 mg/kg) plus NAC (75 mg/kg) also limited injury in the rat CCI model. The therapeutic time window of MINO plus NAC was then tested in the CHI and CCI models. Mice and rats could acquire an active place avoidance task when MINO plus NAC was first dosed at 12 h post-injury. A first dose at 12 h also limited gray matter injury in the hippocampus and preserved myelin in multiple white matter tracts. Mice and rats acquired Barnes maze when MINO plus NAC was first dosed at 24 h post-injury. These data suggest that MINO (22.5 mg/kg) plus NAC (75 mg/kg) remain potent when dosed at clinically useful time windows. Both MINO and NAC are drugs approved by the Food and Drug Administration and have been administered safely to patients in clinical trials at the doses in the new formulation. This suggests that the drug combination of MINO plus NAC may be effective in treating patients with TBI.
Insights
A new formulation of minocycline (MINO) plus N-acetylcysteine (NAC) shows potent neuroprotective effects in traumatic brain injury (TBI) models. This combination is effective even when administered up to 24 hours post-injury, suggesting potential clinical applications.
Area of Science:
- Neuroscience
- Pharmacology
- Traumatic Brain Injury Research
Background:
- Traumatic brain injury (TBI) lacks effective pharmacological treatments.
- Current therapeutic strategies for TBI often lack sufficient potency within clinically relevant time windows.
- Minocycline (MINO) and N-acetylcysteine (NAC) have previously shown synergistic benefits in TBI models when dosed early.
Purpose of the Study:
- To evaluate a new, more potent formulation of MINO and NAC for TBI treatment.
- To determine the therapeutic time window for the MINO-NAC combination in TBI models.
- To assess the efficacy of the optimized MINO-NAC formulation in preclinical TBI models.
Main Methods:
- Utilized mouse closed head injury (CHI) and rat controlled cortical impact (CCI) models of TBI.
- Titrated concentrations of MINO and NAC to identify an optimized, more potent combination (22.5 mg/kg MINO + 75 mg/kg NAC).
- Assessed cognitive function (active place avoidance, Barnes maze) and neuropathological outcomes (hippocampal injury, white matter preservation) at various post-injury dosing times (12h, 24h).
Main Results:
- The optimized MINO (22.5 mg/kg) + NAC (75 mg/kg) formulation demonstrated increased potency in both CHI and CCI models.
- The drug combination effectively limited gray matter injury and preserved myelin when first administered up to 12 hours post-injury.
- Cognitive improvements were observed in both mouse and rat models even when the initial dose was given 24 hours after TBI.
- Both MINO and NAC are FDA-approved and safely administered at these doses, suggesting a favorable safety profile.
Conclusions:
- The optimized combination of minocycline and N-acetylcysteine exhibits significant neuroprotective effects in TBI models.
- This therapeutic strategy remains potent within extended, clinically relevant time windows (up to 24 hours post-injury).
- The established safety profile of MINO and NAC at these doses supports their potential for clinical translation in TBI treatment.
More Related Videos
07:05Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
Published on: January 3, 2017
09:52Modified Roller Tube Method for Precisely Localized and Repetitive Intermittent Imaging During Long-term Culture of Brain Slices in an Enclosed System
Published on: December 28, 2017
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists